6-(Azaindol-2-yl)pyridine-3-sulfonamides as potent and selective inhibitors targeting hepatitis C virus NS4B
摘要:
A structure-activity relationship investigation of various 6-(azaindol-2-yl)pyridine-3-sulfonamides using the HCV replicon cell culture assay led to the identification of a potent series of 7-azaindoles that target the hepatitis C virus NS4B. Compound 2ac, identified via further optimization of the series, has excellent potency against the HCV 1b replicon with an EC50 of 2 nM and a selectivity index of >5000 with respect to cellular GAPDH RNA. Compound 2ac also has excellent oral plasma exposure levels in rats, dogs and monkeys and has a favorable liver to plasma distribution profile in rats. (C) 2015 Elsevier Ltd. All rights reserved.
The present invention is directed to compounds and forms and pharmaceutical compositions thereof useful for treating a viral infection, or for affecting viral activity by modulating viral replication.
本发明涉及化合物及其形式和制药组合物,可用于治疗病毒感染,或通过调节病毒复制来影响病毒活性。
[EN] COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT<br/>[FR] COMPOSÉS ET PROCÉDÉS POUR UN TRAITEMENT ANTIVIRAL
申请人:SCHERING CORP
公开号:WO2010117935A1
公开(公告)日:2010-10-14
The present invention is directed to compounds of formula (I) and forms and pharmaceutical compositions thereof useful for treating a viral infection, or for affecting viral activity by modulating viral replication.
本发明涉及式(I)的化合物、形式和药物组合物,用于治疗病毒感染,或通过调节病毒复制来影响病毒活性。
COMBINATIONS OF A HCV INHIBITOR SUCH AS BICYCLIC PYRROLE DERIVATIVES AND A THERAPEUTIC AGENT